Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
Research & Development
Vifor Pharma AG
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
V
|
Vifor Pharma AG
SIX:VIFN
|
Research & Development
-CHf212.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
Novartis AG
SIX:NOVN
|
Research & Development
-$10.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Research & Development
-$9m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Roche Holding AG
SIX:ROG
|
Research & Development
-CHf13.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Research & Development
-$831m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Research & Development?
Research & Development
-212.5m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Research & Development amounts to -212.5m CHF.
What is Vifor Pharma AG's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was 15%. The average annual Research & Development growth rates for Vifor Pharma AG have been -1% over the past three years , -12% over the past five years .